NASDAQ:PRAX Praxis Precision Medicines (PRAX) Stock Price, News & Analysis $280.14 -3.42 (-1.21%) Closing price 04:00 PM EasternExtended Trading$283.70 +3.56 (+1.27%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Praxis Precision Medicines Stock (NASDAQ:PRAX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PRAX alerts:Sign Up Key Stats Today's Range$272.17▼$289.4750-Day Range$280.14▼$386.3352-Week Range$50.31▼$392.70Volume435,152 shsAverage Volume475,285 shsMarket Capitalization$7.82 billionP/E RatioN/ADividend YieldN/APrice Target$613.26Consensus RatingModerate Buy Company Overview Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. The company uses insights from human genetics, neuroscience and its Cerebrum™ platform to identify and advance medicines for conditions in which existing treatment options may be limited. Praxis’ pipeline has included investigational treatments for epilepsies and other neurological disorders, including developmental and epileptic encephalopathies, essential tremor and movement-related conditions. Its research programs include small-molecule medicines designed to modulate neuronal ion channels and antisense oligonucleotide therapies intended to address specific genetic drivers of disease. The company’s drug candidates remain subject to clinical testing and regulatory review. Founded in 2015 and headquartered in Boston, Massachusetts, Praxis conducts research and clinical development activities through collaborations and studies in the United States and other regions. The company is led by President and Chief Executive Officer Marcio Souza.AI Generated. May Contain Errors. Read More Praxis Precision Medicines Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScorePRAX MarketRank™: Praxis Precision Medicines scored higher than 48% of companies evaluated by MarketBeat, and ranked 617th out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingPraxis Precision Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.95, and is based on 3 strong buy ratings, 15 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialPraxis Precision Medicines has a consensus price target of $613.26, representing about 118.9% upside from its current price of $280.14.Amount of Analyst CoveragePraxis Precision Medicines has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Praxis Precision Medicines' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Praxis Precision Medicines are expected to grow in the coming year, from ($13.90) to ($11.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Praxis Precision Medicines is -21.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Praxis Precision Medicines is -21.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPraxis Precision Medicines has a P/B Ratio of 8.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Praxis Precision Medicines' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.02% of the float of Praxis Precision Medicines has been sold short.Short Interest Ratio / Days to CoverPraxis Precision Medicines has a short interest ratio ("days to cover") of 14.88, which indicates bearish sentiment.Change versus previous monthShort interest in Praxis Precision Medicines has recently increased by 1.47%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPraxis Precision Medicines does not currently pay a dividend.Dividend GrowthPraxis Precision Medicines does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment0.09 News SentimentPraxis Precision Medicines has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Praxis Precision Medicines this week, compared to 7 articles on an average week.Search Interest6 people have searched for PRAX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Praxis Precision Medicines to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Praxis Precision Medicines insiders have not sold or bought any company stock.Percentage Held by Insiders3.00% of the stock of Praxis Precision Medicines is held by insiders.Percentage Held by Institutions67.84% of the stock of Praxis Precision Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Praxis Precision Medicines' insider trading history. Receive PRAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Praxis Precision Medicines and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRAX Stock News HeadlinesPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | globenewswire.comHead-To-Head Comparison: Actinium Pharmaceuticals (NYSE:ATNM) versus Praxis Precision Medicines (NASDAQ:PRAX)October 2, 2026 | americanbankingnews.comElon pays this company. Every time.Every Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Starlink dish and AI satellite Elon launches. When Nvidia tried to buy the company, Elon reportedly fought the deal. Now his filing for 1,000,000 satellites could expand its revenue stream sharply. Dylan believes the stock could see significant movement starting October 24th.October 6 at 1:00 AM | Behind the Markets (Ad)Praxis Precision Medicines (NASDAQ:PRAX) Earns Buy Rating from Needham & Company LLCSeptember 26, 2026 | americanbankingnews.comPraxis Precision Medicines Inc (PRAX)September 19, 2026 | in.investing.comPraxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade)September 12, 2026 | seekingalpha.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2026 | globenewswire.comS&P 500 Futures Drop in Premarket Trading; Praxis Precision Meds, Science Applications LeadAugust 31, 2026 | barrons.comSee More Headlines PRAX Stock Analysis - Frequently Asked Questions How have PRAX shares performed this year? Praxis Precision Medicines' stock was trading at $294.74 at the beginning of 2026. Since then, PRAX stock has decreased by 5.0% and is now trading at $280.14. How were Praxis Precision Medicines' earnings last quarter? Praxis Precision Medicines, Inc. (NASDAQ:PRAX) posted its quarterly earnings results on Thursday, August, 6th. The company reported ($2.87) EPS for the quarter, beating the consensus estimate of ($3.67) by $0.80. Read the conference call transcript. When did Praxis Precision Medicines' stock split? Praxis Precision Medicines's stock reverse split before market open on Wednesday, November 29th 2023.The 1-15 reverse split was announced on Wednesday, November 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Praxis Precision Medicines IPO? Praxis Precision Medicines (PRAX) raised $170 million in an initial public offering on Friday, October 16th 2020. The company issued 10,000,000 shares at a price of $16.00-$18.00 per share. Cowen, Evercore ISI, Piper Sandler and Wedbush PacGrow served as the underwriters for the IPO and Blackstone Capital Markets was co-manager. How do I buy shares of Praxis Precision Medicines? Shares of PRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Praxis Precision Medicines own? Based on aggregate information from My MarketBeat watchlists, some other companies that Praxis Precision Medicines investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings8/06/2026Today10/06/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 PRAX's financial health is in the Green zone, according to TradeSmith. PRAX has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PRAX CIK1689548 Webwww.praxismedicines.com Phone617-300-8460FaxN/AEmployees168Year Founded2015Price Target and Rating Average Price Target for Praxis Precision Medicines$613.26 High Price Target$1,201.00 Low Price Target$162.00 Potential Upside/Downside+118.9%Consensus RatingModerate Buy Rating Score (0-4)2.95 Research Coverage20 Analysts Profitability EPS (Trailing Twelve Months)($12.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$303.27 million Net MarginsN/A Pretax MarginN/A Return on Equity-34.15% Return on Assets-32.42% Debt Debt-to-Equity RatioN/A Current Ratio15.73 Quick Ratio15.73 Sales & Book Value Annual Sales$8.55 million Price / Sales914.80 Cash FlowN/A Price / Cash FlowN/A Book Value$34.85 per share Price / Book8.04Miscellaneous Outstanding Shares27,920,000Free Float27,082,000Market Cap$7.82 billion OptionableOptionable Beta2.79 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:PRAX) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersNvidia’s record quarter could send this new type of AI soaringNvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire ye...Brownstone Research | SponsoredThey're not telling you how bad this could getValuations have reached levels seen only a handful of times in the past century, while debt concerns and tarif...Parkview Capital Group | SponsoredThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Praxis Precision Medicines With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRAX Stock Alerts